AlHarbi M, Mobark N, AlJabarat W, ElBardis H, Alsolme E, Hamdan A
Oncotarget. 2023; 14:580-594.
PMID: 37306523
PMC: 10259259.
DOI: 10.18632/oncotarget.28457.
Khalaf H, Mohammed A, Shukur S, Alhalabi N, Almothafar B, Hassan M
J Med Life. 2022; 15(10):1318-1321.
PMID: 36420288
PMC: 9675305.
DOI: 10.25122/jml-2022-0296.
Sekine M, Nishino K, Enomoto T
Cancers (Basel). 2021; 13(11).
PMID: 34071148
PMC: 8197088.
DOI: 10.3390/cancers13112562.
Chowdhury S, Khatun M, Khan T, Laila A
Asian Pac J Cancer Prev. 2020; 21(8):2265-2270.
PMID: 32856854
PMC: 7771933.
DOI: 10.31557/APJCP.2020.21.8.2265.
Ju Y, Wang L, Ta S, Shu R, Yang S, Gao X
Oncol Lett. 2019; 18(3):2885-2890.
PMID: 31452768
PMC: 6704318.
DOI: 10.3892/ol.2019.10646.
Novel Germline Mutations of and in Korean Familial Breast Cancer Patients.
Kim H, Shin M, Lee R, Park M, Kweon S
Chonnam Med J. 2019; 55(2):99-103.
PMID: 31161121
PMC: 6536435.
DOI: 10.4068/cmj.2019.55.2.99.
Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer C, Tan Y, Muhr D, Rappaport C, Gschwantler-Kaulich D, Grimm C
Cancer Med. 2019; 8(4):1875-1881.
PMID: 30821131
PMC: 6488144.
DOI: 10.1002/cam4.2000.
Genetics of breast cancer in African populations: a literature review.
Abbad A, Baba H, Dehbi H, Elmessaoudi-Idrissi M, Elyazghi Z, Abidi O
Glob Health Epidemiol Genom. 2018; 3:e8.
PMID: 30263132
PMC: 6152487.
DOI: 10.1017/gheg.2018.8.
Association of APEX1 and OGG1 gene polymorphisms with breast cancer risk among Han women in the Gansu Province of China.
Wang T, Wang H, Yang S, Guo H, Zhang B, Guo H
BMC Med Genet. 2018; 19(1):67.
PMID: 29720094
PMC: 5930440.
DOI: 10.1186/s12881-018-0578-9.
Prevalence and Spectrum of BRCA1/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing.
Liang Y, Yang X, Li H, Zhu A, Guo Z, Li M
Med Sci Monit. 2018; 24:2465-2475.
PMID: 29681614
PMC: 5936051.
DOI: 10.12659/msm.905812.
A comprehensive analysis of BRCA2 gene: focus on mechanistic aspects of its functions, spectrum of deleterious mutations, and therapeutic strategies targeting BRCA2-deficient tumors.
Shailani A, Kaur R, Munshi A
Med Oncol. 2018; 35(3):18.
PMID: 29387975
DOI: 10.1007/s12032-018-1085-8.
Evaluation of reported pathogenic variants and their frequencies in a Japanese population based on a whole-genome reference panel of 2049 individuals.
Yamaguchi-Kabata Y, Yasuda J, Tanabe O, Suzuki Y, Kawame H, Fuse N
J Hum Genet. 2017; 63(2):213-230.
PMID: 29192238
DOI: 10.1038/s10038-017-0347-1.
Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang X, Devi B, Sung H, Guida J, Mucaki E, Xiao Y
Breast Cancer Res Treat. 2017; 165(3):687-697.
PMID: 28664506
PMC: 7032652.
DOI: 10.1007/s10549-017-4356-8.
International patterns and trends in ovarian cancer incidence, overall and by histologic subtype.
Coburn S, Bray F, Sherman M, Trabert B
Int J Cancer. 2017; 140(11):2451-2460.
PMID: 28257597
PMC: 5595147.
DOI: 10.1002/ijc.30676.
Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis.
Bu R, Siraj A, Al-Obaisi K, Beg S, Al Hazmi M, Ajarim D
Int J Cancer. 2016; 139(5):1091-7.
PMID: 27082205
PMC: 5111783.
DOI: 10.1002/ijc.30143.
Cumulative BRCA mutation analysis in the Greek population confirms that homogenous ethnic background facilitates genetic testing.
Tsigginou A, Vlachopoulos F, Arzimanoglou I, Zagouri F, Dimitrakakis C
Hered Cancer Clin Pract. 2015; 13(1):17.
PMID: 26300996
PMC: 4545329.
DOI: 10.1186/s13053-015-0037-y.
Comprehensive spectrum of BRCA1 and BRCA2 deleterious mutations in breast cancer in Asian countries.
Kwong A, Shin V, Ho J, Kang E, Nakamura S, Teo S
J Med Genet. 2015; 53(1):15-23.
PMID: 26187060
PMC: 4681590.
DOI: 10.1136/jmedgenet-2015-103132.
Transcriptomics profiling study of breast cancer from Kingdom of Saudi Arabia revealed altered expression of Adiponectin and Fatty Acid Binding Protein4: Is lipid metabolism associated with breast cancer?.
Merdad A, Karim S, Schulten H, Jayapal M, Dallol A, Buhmeida A
BMC Genomics. 2015; 16 Suppl 1:S11.
PMID: 25923423
PMC: 4315151.
DOI: 10.1186/1471-2164-16-S1-S11.
A novel recurrent CHEK2 Y390C mutation identified in high-risk Chinese breast cancer patients impairs its activity and is associated with increased breast cancer risk.
Wang N, Ding H, Liu C, Li X, Wei L, Yu J
Oncogene. 2015; 34(40):5198-205.
PMID: 25619829
DOI: 10.1038/onc.2014.443.
Minor role of BRCA2 mutation (Exon2 and Exon11) in patients with early-onset breast cancer amongst Iranian Azeri-Turkish women.
Karimian Fathi N, Shekari Khaniani M, Montazeri V, Mansoori Derakhshan S
Iran J Basic Med Sci. 2014; 17(2):108-11.
PMID: 24711893
PMC: 3976747.